Fact CheckerSign in

NCT07379489Not yet recruiting

Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma

Efficacy of Postoperative Adjuvant PD-1 Inhibitors Guided by a Deep Learning Model: a Multicenter, Prospective Cohort Study

Source: ClinicalTrials.gov · Last updated 30 Jan 2026

Brief summary (registry, in English)

Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
300 (estimated)
First submitted
23 Jan 2026
Start date
31 Jan 2026
Primary completion date
31 Dec 2029
Lead sponsor
Tongji Hospital
NCT number
NCT07379489

What you commit to

  • Study type: Observational
  • Planned participants: 300
  • From 31 Jan 2026 to the primary completion date, 31 Dec 2029
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • prior treatments for HCC;
  • received other adjuvant therapy.

Other illness

  • history of other malignancies or recurrent HCC;
  • mixed or other types of liver cancer;

Other

  • extrahepatic metastasis;
  • ongoing severe postoperative complications;

Who the study is looking for

  • Aged between 18 and 75;
  • achieved complete tumor resection;
  • histological verification of HCC;
  • liver function classified as Child-Pugh grade A or B;
  • No other serious systemic disease or organ dysfunction.

Age in the registry: 18 years to 75 years · Sex: All

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.